Literature DB >> 22411246

Multiple sclerosis.

Elżbieta Miller1.   

Abstract

Multiple sclerosis (MS) is a chronic, complex neurological disease with a variable clinical course in which several pathophysiological mechanisms such as axonal/ neuronal damage, demyelination, inflammation, gliosis, remyelination and repair, oxidative injury and excitotoxicity, alteration of the immune system as well as biochemical disturbances and disruption of blood-brain barrier are involved.(1,2) Exacerbations of MS symptoms reflect inflammatory episodes, while the neurodegenerative aspects of gliosis and axonal loss result in the progression of disability. The precise aetiology of MS is not yet known, although epidemiological data indicate that it arises from a complex interactions between genetic susceptibility and environmental factors.(3) In this chapter the brain structures and processes involved in immunopathogenesis of MS are presented. Additionally, clinical phenotypes and biomarkers of MS are showed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22411246     DOI: 10.1007/978-1-4614-0653-2_17

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  30 in total

1.  Design of biodegradable nanoparticles to modulate phenotypes of antigen-presenting cells for antigen-specific treatment of autoimmune disease.

Authors:  Eiji Saito; Robert Kuo; Kevin R Kramer; Nishant Gohel; David A Giles; Bethany B Moore; Stephen D Miller; Lonnie D Shea
Journal:  Biomaterials       Date:  2019-08-17       Impact factor: 12.479

2.  Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot study.

Authors:  Paolo Riccio; Rocco Rossano; Marilena Larocca; Vincenzo Trotta; Ilario Mennella; Paola Vitaglione; Michele Ettorre; Antonio Graverini; Alessandro De Santis; Elisabetta Di Monte; Maria Gabriella Coniglio
Journal:  Exp Biol Med (Maywood)       Date:  2016-01-18

Review 3.  New and emerging immune-targeted drugs for the treatment of multiple sclerosis.

Authors:  Alan M Palmer
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

Review 4.  Myeloperoxidase: A new player in autoimmunity.

Authors:  Anna Strzepa; Kirkwood A Pritchard; Bonnie N Dittel
Journal:  Cell Immunol       Date:  2017-05-10       Impact factor: 4.868

Review 5.  Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.

Authors:  Heinz Wiendl; Catharina C Gross
Journal:  Nat Rev Neurol       Date:  2013-06-04       Impact factor: 42.937

Review 6.  Physiology and pathophysiology of the blood-brain barrier: P-glycoprotein and occludin trafficking as therapeutic targets to optimize central nervous system drug delivery.

Authors:  Gwen McCaffrey; Thomas P Davis
Journal:  J Investig Med       Date:  2012-12       Impact factor: 2.895

7.  Blocking initial infiltration of pioneer CD8(+) T-cells into the CNS via inhibition of SHP-2 ameliorates experimental autoimmune encephalomyelitis in mice.

Authors:  Qiong Luo; Yang Sun; Fang-Yuan Gong; Wen Liu; Wei Zheng; Yan Shen; Zi-Chun Hua; Qiang Xu
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

8.  Markers of oxidative/nitrative damage of plasma proteins correlated with EDSS and BDI scores in patients with secondary progressive multiple sclerosis.

Authors:  Agnieszka Morel; Michał Bijak; Marta Niwald; Elżbieta Miller; Joanna Saluk
Journal:  Redox Rep       Date:  2017-05-19       Impact factor: 4.412

Review 9.  Modern Technologies in the Rehabilitation of Patients with Multiple Sclerosis and Their Potential Application in Times of COVID-19.

Authors:  Ewa Zasadzka; Tomasz Trzmiel; Anna Pieczyńska; Katarzyna Hojan
Journal:  Medicina (Kaunas)       Date:  2021-05-30       Impact factor: 2.430

10.  Multiple sclerosis and the blood-central nervous system barrier.

Authors:  Alan M Palmer
Journal:  Cardiovasc Psychiatry Neurol       Date:  2013-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.